Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Pharma
With key FDA nod in MASH, Novo's Wegovy scores 3rd indication
With a new FDA nod, Novo's GLP-1 Wegovy has scored its third indication and become the second drug approved in a severe form of fatty liver disease.
Fraiser Kansteiner
Aug 18, 2025 10:08am
Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia
Aug 15, 2025 8:31am
Madrigal's first-ever MASH drug beats sales projections again
May 2, 2025 11:00am
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Sales strong for Madrigal's Rezdiffra, but shares down 13%
Aug 7, 2024 2:56pm
With FDA nod for Iqirvo, Ipsen and Genfit will take on Intercept
Jun 11, 2024 11:07am
